These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 27524889)

  • 21. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide significantly decreases glycated haemoglobin compared with once-daily liraglutide in Japanese patients with type 2 diabetes: 52 weeks of treatment in a randomized phase III study.
    Odawara M; Miyagawa J; Iwamoto N; Takita Y; Imaoka T; Takamura T
    Diabetes Obes Metab; 2016 Mar; 18(3):249-57. PubMed ID: 26661514
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patient preferences and health state utilities associated with dulaglutide and semaglutide injection devices among patients with type 2 diabetes in Italy.
    Boye KS; Matza LS; Stewart KD; Jordan J; Biricolti G; Del Santo S; Perez-Nieves M; Federici MO; Gentilella R; Losi S; Norrbacka K
    J Med Econ; 2019 Aug; 22(8):806-813. PubMed ID: 31010349
    [No Abstract]   [Full Text] [Related]  

  • 23. The Real-World Observational Prospective Study of Health Outcomes with Dulaglutide and Liraglutide in Patients with Type 2 Diabetes (TROPHIES): Patient disposition, clinical characteristics and treatment persistence at 12 months.
    Guerci B; Giorgino F; Sapin H; Boye K; Lebrec J; Federici MO; Heitmann E; Dib A; Füchtenbusch M; García-Pérez LE
    Diabetes Obes Metab; 2022 Dec; 24(12):2373-2382. PubMed ID: 35876235
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Understanding patient cost-sharing thresholds for diabetes treatment attributes via a discrete choice experiment.
    Panchal R; Nguyen D; Ghule P; Li N; Giannouchos T; Pan RJ; Biskupiak J; Britton L; Nohavec R; Slager S; Ngorsuraches S; Brixner D
    J Manag Care Spec Pharm; 2023 Feb; 29(2):139-150. PubMed ID: 36705280
    [No Abstract]   [Full Text] [Related]  

  • 25. The cost-effectiveness of dulaglutide versus liraglutide for the treatment of type 2 diabetes mellitus in Spain in patients with BMI ≥30 kg/m
    Dilla T; Alexiou D; Chatzitheofilou I; Ayyub R; Lowin J; Norrbacka K
    J Med Econ; 2017 May; 20(5):443-452. PubMed ID: 28008768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Valuing injection frequency and other attributes of type 2 diabetes treatments in Australia: a discrete choice experiment.
    Fifer S; Rose J; Hamrosi KK; Swain D
    BMC Health Serv Res; 2018 Aug; 18(1):675. PubMed ID: 30165844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
    Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
    Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preference for Type 2 Diabetes Therapies in the United States: A Discrete Choice Experiment.
    Shubrook JH; Radin M; Ali SN; Chubb B; DiPietrantonio K; Collings H; Wyn R; Smith M
    Adv Ther; 2022 Sep; 39(9):4114-4130. PubMed ID: 35797004
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Once-weekly glucagon-like peptide-1 receptor agonist dulaglutide is non-inferior to once-daily liraglutide and superior to placebo in Japanese patients with type 2 diabetes: a 26-week randomized phase III study.
    Miyagawa J; Odawara M; Takamura T; Iwamoto N; Takita Y; Imaoka T
    Diabetes Obes Metab; 2015 Oct; 17(10):974-83. PubMed ID: 26179187
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjunctive Role of Glucagon-Like Peptide-1 Receptor Agonists in the Management of Type 1 Diabetes Mellitus.
    Harris KB; Boland CL
    Pharmacotherapy; 2016 Sep; 36(9):1011-20. PubMed ID: 27485823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model.
    Yuan S; Wu Y
    Front Public Health; 2023; 11():1201818. PubMed ID: 37744474
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial.
    Inagaki N; Takeuchi M; Oura T; Imaoka T; Seino Y
    Lancet Diabetes Endocrinol; 2022 Sep; 10(9):623-633. PubMed ID: 35914543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of once-weekly glucagon-like peptide-1 receptor agonists compared with exenatide and liraglutide in type 2 diabetes: a systemic review of randomised controlled trials.
    Xue X; Ren Z; Zhang A; Yang Q; Zhang W; Liu F
    Int J Clin Pract; 2016 Aug; 70(8):649-56. PubMed ID: 27456750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Health state utilities associated with treatment process for oral and injectable GLP-1 receptor agonists for type 2 diabetes.
    Matza LS; Cutts KN; Stewart KD; Norrbacka K; García-Pérez LE; Boye KS
    Qual Life Res; 2021 Jul; 30(7):2033-2043. PubMed ID: 33886044
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
    Tanaka K; Okada Y; Tokutsu A; Tanaka Y
    Sci Rep; 2022 Jan; 12(1):154. PubMed ID: 34997102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discrete Choice Experiment to Understand Japanese Patients' and Physicians' Preferences for Preventive Treatments for Migraine.
    Seo J; Tervonen T; Ueda K; Zhang D; Danno D; Tockhorn-Heidenreich A
    Neurol Ther; 2023 Apr; 12(2):651-668. PubMed ID: 36848008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glucagon-like peptide-1 receptor agonists versus insulin glargine for type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
    Li WX; Gou JF; Tian JH; Yan X; Yang L
    Curr Ther Res Clin Exp; 2010 Aug; 71(4):211-38. PubMed ID: 24688145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
    Nauck MA; Quast DR; Wefers J; Meier JJ
    Mol Metab; 2021 Apr; 46():101102. PubMed ID: 33068776
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.